Dr. Nigel S. Key, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 73
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
- Hematology & Oncology Physician primary
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 73
- Services billed
- 115
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 38 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Chapel Hill, NC | 69 |
| Celecoxib Other prescribers in Chapel Hill, NC | 51 |
| Eliquis (apixaban) Other prescribers in Chapel Hill, NC | 30 |
| Tranexamic Acid | 30 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Chapel Hill, NC | 28 |
| Xarelto (rivaroxaban) Other prescribers in Chapel Hill, NC | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $23,267 in total to this clinician.
| Csl Behring | $8,879 |
|---|---|
| BioMarin Pharmaceutical Inc. | $8,212 |
| Pfizer Inc. | $6,050 |
| Novo Nordisk Inc | $125 |
| Consulting Fee | $14,262 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $8,879 |
| Food and Beverage | $125 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Csl Behring Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,697 |
| Csl Behring Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,094 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| Csl Behring Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $1,068 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| BioMarin Pharmaceutical Inc. Dec 31, 2025 | Consulting Fee | $1,369 |
| Csl Behring Dec 7, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $722 |
| Csl Behring Nov 17, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $1,059 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Csl Behring Sep 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $1,068 |
| Csl Behring Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,094 |
| Csl Behring Aug 1, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $403 |
| Csl Behring Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $2,697 |
| Csl Behring Feb 5, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $681 |
| Csl Behring Jan 15, 2025 | Compensation for services other than consulting (speaking, faculty) HEMGENIX · Hematology · in-kind | $156 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $158,748 in research payments for these studies, mostly to the institutions running them.
- Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Csl Behring · Enrolling by invitation · NCT05962398 - BMN 270-401
BioMarin Pharmaceutical Inc. - HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
Csl Behring · Completed · NCT03569891
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.